Amphastar Pharmaceuticals, Inc. Gain (Loss) on Interest Rate Derivative Instruments Not Designated as Hedging Instruments
Amphastar Pharmaceuticals, Inc. (AMPH) reported Gain (Loss) on Interest Rate Derivative Instruments Not Designated as Hedging Instruments of $416.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnInterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstruments · last filed 2026-05-07
- Amphastar Pharmaceuticals, Inc. gain (loss) on interest rate derivative instruments not designated as hedging instruments for the quarter ending 2026-03-31 was $416.00K.
- Amphastar Pharmaceuticals, Inc. gain (loss) on interest rate derivative instruments not designated as hedging instruments for the quarter ending 2025-03-31 was -$2.14M, a 146.11% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. gain (loss) on interest rate derivative instruments not designated as hedging instruments for the quarter ending 2024-03-31 was $4.64M.
- Amphastar Pharmaceuticals, Inc. gain (loss) on interest rate derivative instruments not designated as hedging instruments for the quarter ending 2023-03-31 was -$195.00K, a 106.47% decline year-over-year.
| Period end | Gain (Loss) on Interest Rate Derivative Instruments Not Designated as Hedging Instruments 3 month | Gain (Loss) on Interest Rate Derivative Instruments Not Designated as Hedging Instruments 6 month |
|---|---|---|
| 2026-03-31 | $416.00K 10-Q · filed 2026-05-07 | |
| 2025-03-31 | -$2.14M 10-Q · filed 2026-05-07 | |
| 2024-03-31 | $4.64M 10-Q · filed 2025-05-08 | |
| 2023-03-31 | -$195.00K 10-Q · filed 2024-05-10 | |
| 2022-06-30 | $3.90M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $3.01M 10-Q · filed 2023-05-09 | |
| 2021-06-30 | $275.00K 10-Q · filed 2022-08-09 | |
| 2021-03-31 | $179.00K 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |